Search

Your search keyword '"Newbold, Kate"' showing total 437 results
Start Over Author "Newbold, Kate"
437 results on '"Newbold, Kate"'

102. Practice patterns for the radical treatment of nasopharyngeal cancer by head and neck oncologists in the United Kingdom

Author

Petkar, Imran, Bhide, Shreerang, Newbold, Kate, Harrington, Kevin, and Nutting, Chris

Subjects
Oncologists, Full Paper, RADIOTHERAPY AND ONCOLOGY - Clinical management and audit, Toxicity and symptom management, Nasopharyngeal Neoplasms, United Kingdom, Head and neck, Radiotherapy & Oncology, Humans, 3D treatment planning/normal tissue sparing, Practice Patterns, Physicians', Head, Neck, Neoplasm Staging
Abstract

Objective: Advances in radiation delivery, imaging techniques, and chemotherapy have significantly improved treatment options for non-metastatic nasopharyngeal cancers (NPC). However, their impact on the practice in the United Kingdom (UK), where this tumour is rare, is unknown. This study examined the current attitudes of UK head and neck oncologists to the treatment of NPC. Methods: UK head and neck oncologists representing 19/23 cancer networks were sent an invitation email with a personalised link to a web-based survey designed to identify the influence of tumour and nodal staging on current NPC management practices. Results: 26/42 (61%) of clinicians responded. Induction chemotherapy followed by concomitant chemoradiation was the treatment of choice for Stage III (69%) and IVa/b (96%), with cisplatin and 5-fluorouracil combination being the most commonly used induction chemotherapy regimen (88%). 16 centres (61%) used a geometric approach, adding variable margins of 0–10 mm to the gross tumour volume to define their therapeutic dose clinical target volume. 54% of respondents used 3 radiotherapy (RT) prescription doses to treat NPC. Retropharyngeal nodal region irradiation policy was inconsistent, with nearly one-quarter treating the entire group to a radical dose. Conclusion: Significant heterogeneity currently exists in the RT practice of NPC in the UK. A consensus regarding the optimal curative, function-sparing treatment paradigm for NPC is necessary to ensure cancer survivors have satisfactory long-term health-related quality of life. Advances in knowledge: This is the first study to highlight the significant variation in RT practice of NPC in the UK.

Published
2018

103. Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T

Author

Panek, Rafal, Welsh, Liam, Dunlop, Alex, Wong, Kee H., Riddell, Angela M., Koh, Dow‐Mu, Schmidt, Maria A., Doran, Simon, Mcquaid, Dualta, Hopkinson, Georgina, Richardson, Cheryl, Nutting, Christopher M., Bhide, Shreerang A., Harrington, Kevin J., Robinson, Simon P., Newbold, Kate L., and Leach, Martin O.

Subjects
Male, Observer Variation, hypoxia, Squamous Cell Carcinoma of Head and Neck, Reproducibility of Results, Middle Aged, Magnetic Resonance Imaging, Sensitivity and Specificity, head and neck, Oxygen, Head and Neck Neoplasms, Image Interpretation, Computer-Assisted, Biomarkers, Tumor, Carcinoma, Squamous Cell, Humans, Female, Neuro, Original Research, BOLD, MRI
Abstract

Purpose To determine whether quantitation of T2* is sufficiently repeatable and sensitive to detect clinically relevant oxygenation levels in head and neck squamous cell carcinoma (HNSCC) at 3T. Materials and Methods Ten patients with newly diagnosed locally advanced HNSCC underwent two magnetic resonance imaging (MRI) scans between 24 and 168 hours apart prior to chemoradiotherapy treatment. A multiple gradient echo sequence was used to calculate T2* maps. A quadratic function was used to model the blood transverse relaxation rate as a function of blood oxygenation. A set of published coefficients measured at 3T were incorporated to account for tissue hematocrit levels and used to plot the dependence of fractional blood oxygenation (Y) on T2* values, together with the corresponding repeatability range. Repeatability of T2* using Bland–Altman analysis, and calculation of limits of agreement (LoA), was used to assess the sensitivity, defined as the minimum difference in fractional blood oxygenation that can be confidently detected. Results T2* LoA for 22 outlined tumor volumes were 13%. The T2* dependence of fractional blood oxygenation increases monotonically, resulting in increasing sensitivity of the method with increasing blood oxygenation. For fractional blood oxygenation values above 0.11, changes in T2* were sufficient to detect differences in blood oxygenation greater than 10% (Δ T2* > LoA for ΔY > 0.1). Conclusion Quantitation of T2* at 3T can detect clinically relevant changes in tumor oxygenation within a wide range of blood volumes and oxygen tensions, including levels reported in HNSCC. J. Magn. Reson. Imaging 2016;44:72–80.

Published
2016

105. Thyroid cancer causing obstruction of the great veins in the neck

Author

Haq Masud, Newbold Kate, Dandekar Prasad, Hyer Steve L, Wechalakar Kshama, and Harmer Clive

Subjects
Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background and aims To report our experience and review the literature of thyroid cancer obstructing the great veins in the neck, highlighting clinical aspects and response to treatment. Methods Clinical data were collected from the thyroid cancer register and from follow-up clinic visits of patients referred to the Thyroid Unit at the Royal Marsden Hospital. A Medline literature search was conducted between 1980 and 2007. Results Of 1448 patients with thyroid cancer on our cancer register and treated in our unit over the last 60 years, we identified five patients, four women and one man, aged 43 – 81 years with a median follow up of 28 (24–78) months in whom tumour had occluded the great veins in the neck. All patients underwent total thyroidectomy and all subsequently received ablative 131I with the exception of patient 3 whose post-operative isotope scan shown no significant 131I uptake. External beam radiotherapy to the neck and upper mediastinum was used for residual disease control in the 5 patients. The median survival was 28 months and the disease-free survival was 24 months. One patient remains asymptomatic but with disease 53 months after initial presentation. Survival in this small series is significantly better than that previously reported for this condition. Conclusion A multimodality therapeutic approach comprising surgery, radioiodine and external beam radiotherapy may give the best results for patients in whom thyroid cancer is occluding the great veins.

Published
2008
Full Text
View/download PDF

108. Non-invasive Imaging of Cycling Hypoxia in Head & Neck Cancer Using Intrinsic Susceptibility MRI

Author

Panek, Rafal, Welsh, Liam, Baker, Lauren C.J., Schmidt, Maria A., Wong, Kee H., Riddell, Angela M., Koh, Dow-Mu, Dunlop, Alex, Mcquaid, Dualta, d’Arcy, James A., Bhide, Shreerang A., Harrington, Kevin J., Nutting, Christopher M., Hopkinson, Georgina, Richardson, Cheryl, Box, Carol, Eccles, Suzanne A., Leach, Martin O., Robinson, Simon P., and Newbold, Kate L.

Subjects
Male, Neovascularization, Pathologic, Squamous Cell Carcinoma of Head and Neck, Contrast Media, Magnetic Resonance Imaging, Radiation Tolerance, Xenograft Model Antitumor Assays, Article, Cell Hypoxia, Mice, Treatment Outcome, Head and Neck Neoplasms, Nitroimidazoles, Cell Line, Tumor, Carcinoma, Squamous Cell, Animals, Humans, Female, Lymph Nodes
Published
2017

109. Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Author

Dillon, Magnus T., primary, Grove, Lorna, additional, Newbold, Kate L., additional, Shaw, Heather, additional, Brown, Nicholas F., additional, Mendell, Jeanne, additional, Chen, Shuquan, additional, Beckman, Robert A., additional, Jennings, Anne, additional, Ricamara, Marivic, additional, Greenberg, Jonathan, additional, Forster, Martin, additional, and Harrington, Kevin J., additional

Published
2019
Full Text
View/download PDF

110. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium

Author

Luster, Markus, primary, Aktolun, Cumali, additional, Amendoeira, Isabel, additional, Barczyński, Marcin, additional, Bible, Keith C., additional, Duntas, Leonidas H., additional, Elisei, Rossella, additional, Handkiewicz-Junak, Daria, additional, Hoffmann, Martha, additional, Jarząb, Barbara, additional, Leenhardt, Laurence, additional, Musholt, Thomas J., additional, Newbold, Kate, additional, Nixon, Iain J., additional, Smit, Johannes, additional, Sobrinho-Simões, Manuel, additional, Sosa, Julie Ann, additional, Tuttle, R. Michael, additional, Verburg, Frederik A., additional, Wartofsky, Leonard, additional, and Führer, Dagmar, additional

Published
2019
Full Text
View/download PDF

112. A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.

Author

Schlumberger, Martin, primary, Newbold, Kate, additional, Hasan, Baktiar, additional, Marreaud, Sandrine, additional, Assele, Samson, additional, Licitra, Lisa F., additional, Schoffski, Patrick, additional, Leboulleux, Sophie, additional, Locati, Laura, additional, Godbert, Yann, additional, Rohmer, Vincent, additional, Jarzab, Barbara, additional, Domenico, Salvatore, additional, Bechter, Oliver Edgar, additional, Zanetta, Sylvie, additional, Capdevila, Jaume, additional, Kapiteijn, Ellen, additional, and Bastholt, Lars, additional

Published
2018
Full Text
View/download PDF

113. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)

Author

Wirth, Lori J., primary, Tahara, Makoto, additional, Robinson, Bruce, additional, Francis, Sanjeev, additional, Brose, Marcia S., additional, Habra, Mouhammed Amir, additional, Newbold, Kate, additional, Kiyota, Naomi, additional, Dutcus, Corina E., additional, Mathias, Elton, additional, Guo, Matthew, additional, Sherman, Steven I., additional, and Schlumberger, Martin, additional

Published
2018
Full Text
View/download PDF

116. MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for Radiation Therapy

Author

Gurney-Champion, Oliver J., primary, McQuaid, Dualta, additional, Dunlop, Alex, additional, Wong, Kee H., additional, Welsh, Liam C., additional, Riddell, Angela M., additional, Koh, Dow-Mu, additional, Oelfke, Uwe, additional, Leach, Martin O., additional, Nutting, Christopher M., additional, Bhide, Shreerang A., additional, Harrington, Kevin J., additional, Panek, Rafal, additional, and Newbold, Kate L., additional

Published
2018
Full Text
View/download PDF

117. Medullary Thyroid Cancer Patient’s Assessment of Quality of Life Tools: Results from the QaLM Study

Author

Moss, Laura, Cox, Catrin, Wadsley, Jonathan, Newbold, Kate, Strachan, Mark W.J., Druce, Maralyn, Tolley, Neil, Graham, Kathryn, Jefferies, Sarah, Fresco, Lydia, Sivabalasingham, Suganya, Balfour, Alistair, and Hurt, Chris

Abstract

Background:Medullary thyroid cancer (MTC) is a neuroendocrine tumour and a rare variant of thyroid cancer with different aetiology, presentation and treatment to differentiated thyroid cancer. Currently available thyroid cancer-specific quality of life (QoL) tools focus on issues and treatments more relevant to patients with differentiated thyroid cancer and therefore may not address issues specific to a MTC diagnosis and cancer journey. Method:This prospective multicentre randomised study involved 204 MTC patients completing four quality of life questionnaires (QOLQ) and stating their most and least preferred. The questionnaires were a general instrument, the EORTC QLQ-C30, two disease-specific tools, the MD Anderson Symptom Inventory (MDASI) thyroid module and the City of Hope Quality of Life Scale/THYROID (amended) and the neuroendocrine questionnaire, EORTC QLQ-GINET21. Patients were randomised to complete the four questionnaires in one of 24 possible orders and then answered questions about which tool they preferred. The primary outcome measure was patients’ preferred QoL instrument for describing their concerns and for facilitating communication with their healthcare professional. Secondary analyses looked at differences between preferred QOLQs amongst patient subgroups (WHO performance status [0 and 1+], disease stage: early [T1–3, N0 or N1A], metastatic [T4, any T N1b] and advanced [any T any N M1], and type of MTC [sporadic and inherited]), identification of MTC patients’ least preferred questionnaire and clinicians’ views on the QoL tools in terms of their ability to highlight problems not otherwise ascertained by a standard clinical review. Results:No evidence of a difference was observed for most preferred QOLQ (p= 0.650). There was however evidence of a difference in least preferred questionnaire in the cohort of 128 patients who stated their least preferred questionnaire (p= 0.042), with 36% (46/128) of patients choosing the EORTC QLQ-GI.NET21 questionnaire. Subgroup analyses showed that there was no evidence of a difference in patients’ most preferred questionnaire in sporadic MTC patients (p= 0.637), patients with WHO PS 0 or 1+ (p= 0.844 and p= 0.423) nor when comparing patients with early, advanced local or metastatic disease (p= 0.132, p= 0.463 and p= 0.506, respectively). Similarly, subgroup analyses on patients’ least preferred questionnaires showed no evidence of differences in sporadic MTC patients (p= 0.092), patients with WHO PS 0 or 1+ (p= 0.423 and p= 0.276), nor in early or metastatic disease patients (p= 0.682 and p= 0.345, respectively). There was however some evidence to suggest a difference in least preferred questionnaire in patients with advanced local stage disease (p= 0.059), with 43% (16/37) of these patients choosing the EORTC QLQ-GI.NET21 questionnaire. Conclusions:MTC patients regardless of their performance status, disease aetiology and disease burden did not express a preference for any one particular questionnaire suggesting any of the tools studied could be utilized in this patient cohort. The least preferred questionnaire being a gastrointestinal NET specific tool suggests that diarrhoea was not a significant symptom and concern for the population studied.

Published
2021
Full Text
View/download PDF

119. Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer

Author

Wong, Kee H., primary, Panek, Rafal, additional, Dunlop, Alex, additional, Mcquaid, Dualta, additional, Riddell, Angela, additional, Welsh, Liam C., additional, Murray, Iain, additional, Koh, Dow-Mu, additional, Leach, Martin O., additional, Bhide, Shreerang A., additional, Nutting, Christopher M., additional, Oyen, Wim J., additional, Harrington, Kevin J., additional, and Newbold, Kate L., additional

Published
2017
Full Text
View/download PDF

122. Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI

Author

Panek, Rafal, primary, Welsh, Liam, additional, Baker, Lauren C.J., additional, Schmidt, Maria A., additional, Wong, Kee H., additional, Riddell, Angela M., additional, Koh, Dow-Mu, additional, Dunlop, Alex, additional, Mcquaid, Dualta, additional, d'Arcy, James A., additional, Bhide, Shreerang A., additional, Harrington, Kevin J., additional, Nutting, Christopher M., additional, Hopkinson, Georgina, additional, Richardson, Cheryl, additional, Box, Carol, additional, Eccles, Suzanne A., additional, Leach, Martin O., additional, Robinson, Simon P., additional, and Newbold, Kate L., additional

Published
2017
Full Text
View/download PDF

123. Predicting response to radical (chemo)radiotherapy (R-CRT) with circulating HPV DNA and tumor DNA (ctDNA) analysis in locally-advanced head and neck squamous cell carcinoma (LAHNC).

Author

Bhide, Shreerang, primary, Lee, Jen, additional, Garcia-Murillas, Isaac, additional, Cutts, Ros, additional, Hurley, Tara, additional, Grove, Lorna, additional, Nutting, Christopher, additional, Newbold, Kate, additional, Turner, Nicholas C., additional, and Harrington, Kevin, additional

Published
2017
Full Text
View/download PDF

126. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t

Author

Cabanillas, Maria E, Schlumberger, Martin, Jarzab, Barbara, Martins, Renato G., Pacini, Furio, Robinson, Bruce, Mccaffrey, Judith C., Shah, Manisha H., Bodenner, Donald L., Topliss, Duncan, Andresen, Corina, O'Brien, James P., Ren, Min, Funahashi, Yasuhiro, Allison, Roger, Elisei, Rossella, Newbold, Kate, Licitra, Lisa F., Sherman, Steven I., and Ball, Douglas W.

Subjects
Cancer Research, Oncology, phase 2, biomarkers, differentiated thyroid cancer, radioiodine refractory, lenvatinib, multikinase inhibitor
Published
2015

127. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

Author

McLaughlin, Martin, primary, Barker, Holly E., additional, Khan, Aadil A., additional, Pedersen, Malin, additional, Dillon, Magnus, additional, Mansfield, David C., additional, Patel, Radhika, additional, Kyula, Joan N., additional, Bhide, Shreerang A., additional, Newbold, Kate L., additional, Nutting, Christopher M., additional, and Harrington, Kevin J., additional

Published
2017
Full Text
View/download PDF

129. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck

Author

Welsh, Liam, primary, Panek, Rafal, additional, Riddell, Angela, additional, Wong, Kee, additional, Leach, Martin O, additional, Tavassoli, Mahvash, additional, Rahman, Durdana, additional, Schmidt, Maria, additional, Hurley, Tara, additional, Grove, Lorna, additional, Richards, Thomas, additional, Koh, Dow-Mu, additional, Nutting, Christopher, additional, Harrington, Kevin, additional, Newbold, Kate, additional, and Bhide, Shreerang, additional

Published
2016
Full Text
View/download PDF

130. Functional Data Analysis Applied to Modeling of Severe Acute Mucositis and Dysphagia Resulting From Head and Neck Radiation Therapy

Author

Dean, Jamie A., primary, Wong, Kee H., additional, Gay, Hiram, additional, Welsh, Liam C., additional, Jones, Ann-Britt, additional, Schick, Ulrike, additional, Oh, Jung Hun, additional, Apte, Aditya, additional, Newbold, Kate L., additional, Bhide, Shreerang A., additional, Harrington, Kevin J., additional, Deasy, Joseph O., additional, Nutting, Christopher M., additional, and Gulliford, Sarah L., additional

Published
2016
Full Text
View/download PDF

131. Time-resolved angiography with stochastic trajectories for dynamic contrast-enhanced MRI in head and neck cancer: Are pharmacokinetic parameters affected?

Author

Panek, Rafal, primary, Schmidt, Maria A., additional, Borri, Marco, additional, Koh, Dow-Mu, additional, Riddell, Angela, additional, Welsh, Liam, additional, Dunlop, Alex, additional, Powell, Ceri, additional, Bhide, Shreerang A., additional, Nutting, Christopher M., additional, Harrington, Kevin J., additional, Newbold, Kate L., additional, and Leach, Martin O., additional

Published
2016
Full Text
View/download PDF

132. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer

Author

Petkar, Imran, primary, Rooney, Keith, additional, Roe, Justin W. G., additional, Patterson, Joanne M., additional, Bernstein, David, additional, Tyler, Justine M., additional, Emson, Marie A., additional, Morden, James P., additional, Mertens, Kathrin, additional, Miles, Elizabeth, additional, Beasley, Matthew, additional, Roques, Tom, additional, Bhide, Shreerang A., additional, Newbold, Kate L., additional, Harrington, Kevin J., additional, Hall, Emma, additional, and Nutting, Christopher M., additional

Published
2016
Full Text
View/download PDF

133. Management of Invasive Differentiated Thyroid Cancer

Author

Nixon, Iain J., primary, Simo, Ricard, additional, Newbold, Kate, additional, Rinaldo, Alessandra, additional, Suarez, Carlos, additional, Kowalski, Luiz P., additional, Silver, Carl, additional, Shah, Jatin P., additional, and Ferlito, Alfio, additional

Published
2016
Full Text
View/download PDF

134. The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma

Author

Wong, Kee H., primary, Panek, Rafal, additional, Welsh, Liam, additional, Mcquaid, Dualta, additional, Dunlop, Alex, additional, Riddell, Angela, additional, Murray, Iain, additional, Du, Yong, additional, Chua, Sue, additional, Koh, Dow-Mu, additional, Bhide, Shreerang, additional, Nutting, Chris, additional, Oyen, Wim J.G., additional, Harrington, Kevin, additional, and Newbold, Kate L., additional

Published
2016
Full Text
View/download PDF

135. Repeatability and sensitivity of measurements in patients with head and neck squamous cell carcinoma at 3T

Author

Panek, Rafal, primary, Welsh, Liam, additional, Dunlop, Alex, additional, Wong, Kee H., additional, Riddell, Angela M., additional, Koh, Dow‐Mu, additional, Schmidt, Maria A., additional, Doran, Simon, additional, Mcquaid, Dualta, additional, Hopkinson, Georgina, additional, Richardson, Cheryl, additional, Nutting, Christopher M., additional, Bhide, Shreerang A., additional, Harrington, Kevin J., additional, Robinson, Simon P., additional, Newbold, Kate L., additional, and Leach, Martin O., additional

Published
2016
Full Text
View/download PDF

136. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Author

Schlumberger, Martin, primary, Jarzab, Barbara, additional, Cabanillas, Maria E., additional, Robinson, Bruce, additional, Pacini, Furio, additional, Ball, Douglas W., additional, McCaffrey, Judith, additional, Newbold, Kate, additional, Allison, Roger, additional, Martins, Renato G., additional, Licitra, Lisa F., additional, Shah, Manisha H., additional, Bodenner, Donald, additional, Elisei, Rossella, additional, Burmeister, Lynn, additional, Funahashi, Yasuhiro, additional, Ren, Min, additional, O'Brien, James P., additional, and Sherman, Steven I., additional

Published
2016
Full Text
View/download PDF

138. Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.

Author

Newbold, Kate, primary, Elisei, Rossella, additional, Taylor, Matthew Hiram, additional, Krzyzanowska, Monika K., additional, Shah, Manisha H., additional, Hoff, Ana O., additional, Robinson, Bruce, additional, Dutcus, Corina, additional, Song, James, additional, and Habra, Mouhammed Amir, additional

Published
2015
Full Text
View/download PDF

139. Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT.

Author

Brose, Marcia S., primary, Schlumberger, Martin, additional, Tahara, Makoto, additional, Wirth, Lori J., additional, Robinson, Bruce, additional, Elisei, Rossella, additional, Newbold, Kate, additional, Kiyota, Naomi, additional, Hoff, Ana O., additional, Dutcus, Corina, additional, Song, James, additional, Sherman, Steven I., additional, and Taylor, Matthew Hiram, additional

Published
2015
Full Text
View/download PDF

140. Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study

Author

Welsh, Liam, primary, Panek, Rafal, additional, McQuaid, Dualta, additional, Dunlop, Alex, additional, Schmidt, Maria, additional, Riddell, Angela, additional, Koh, Dow-Mu, additional, Doran, Simon, additional, Murray, Iain, additional, Du, Yong, additional, Chua, Sue, additional, Hansen, Vibeke, additional, Wong, Kee H., additional, Dean, Jamie, additional, Gulliford, Sarah, additional, Bhide, Shreerang, additional, Leach, Martin O., additional, Nutting, Christopher, additional, Harrington, Kevin, additional, and Newbold, Kate, additional

Published
2015
Full Text
View/download PDF

142. Brain-Sparing Methods for IMRT of Head and Neck Cancer

Author

Dunlop, Alex, primary, Welsh, Liam, additional, McQuaid, Dualta, additional, Dean, Jamie, additional, Gulliford, Sarah, additional, Hansen, Vibeke, additional, Bhide, Shreerang, additional, Nutting, Chris, additional, Harrington, Kevin, additional, and Newbold, Kate, additional

Published
2015
Full Text
View/download PDF

143. Survey on Paediatric Differentiated Thyroid Cancer Care in Europe.

Author

Dekker, Bernadette L., Newbold, Kate L., Führer, Dagmar, Waguespack, Steven G., Handkiewicz-Junak, Daria, and Links, Thera P.

Subjects
*THYROID cancer, *IODINE isotopes
Abstract

Background/Aims: Thyroid cancer among children is a very rare disease. Although survival is favourable, morbidity caused by the treatment remains considerable, so there is a great need to optimize management by international cooperation. For this reason, the 2016 European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Copenhagen, Denmark, paid considerable attention to this topic and aimed to give an overview of the care for this paediatric patient group in different European countries. Methods: An inventory of data on thyroid cancer treatment among children in Europe was generated by questionnaires focused on treatment and organization of care. Results: The treatment of paediatric thyroid cancer appears to be scattered in each European country with limited centralization of care, and different European countries use different treatment and follow-up protocols. Conclusion: Collaboration in a European network to optimize treatment and minimize long-term consequences for paediatric thyroid cancer survivors is necessary. During this meeting, the ETA-CRN has endorsed the initiative to collaborate on this rare endocrine cancer within a European network. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

144. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).

Author

Schlumberger, Martin, primary, Tahara, Makoto, additional, Wirth, Lori J., additional, Robinson, Bruce, additional, Brose, Marcia S., additional, Elisei, Rossella, additional, Dutcus, Corina E., additional, de las Heras, Begoña, additional, Zhu, Junming, additional, Habra, Mouhammed Amir, additional, Newbold, Kate, additional, Shah, Manisha H., additional, Hoff, Ana O., additional, Gianoukakis, Andrew G, additional, Kiyota, Naomi, additional, Taylor, Matthew Hiram, additional, Kim, Sung-Bae, additional, Krzyzanowska, Monika K, additional, and Sherman, Steven I., additional

Published
2014
Full Text
View/download PDF

146. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck.

Author

Welsh, Liam, Panek, Rafal, Riddell, Angela, Wong, Kee, Leach, Martin O, Tavassoli, Mahvash, Rahman, Durdana, Schmidt, Maria, Hurley, Tara, Grove, Lorna, Richards, Thomas, Koh, Dow-Mu, Nutting, Christopher, Harrington, Kevin, Newbold, Kate, and Bhide, Shreerang

Subjects
CANCER treatment, BLOOD transfusion, CLINICAL trials, COMPARATIVE studies, LONGITUDINAL method, MAGNETIC resonance imaging, HEAD tumors, RESEARCH methodology, MEDICAL cooperation, METASTASIS, RESEARCH, NECK tumors, RESEARCH funding, SQUAMOUS cell carcinoma, EVALUATION research, DIAGNOSIS, TUMOR treatment
Abstract

Background: Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radical chemo-radiation (CRT) frequently receive transfusion with packed red cells (PRCT) during radiotherapy on the basis that PRCT increases tumour oxygenation and overcomes hypoxia-induced radio-resistance. This is likely to be a significant oversimplification given the fact that tumour hypoxia is the result of several intrinsic and extrinsic factors, including many that are not directly related to serum haemoglobin (Hb). Therefore, we have studied the effect of PRCT on tumour oxygenation in a prospective cohort of patients who developed low Hb during radical CRT for HNSCC.Methods: This was a prospective study of 20 patients with HNSCC receiving radical CRT undergoing PRCT for Hb<11.5 g dl-1. Patients underwent pretransfusion and posttransfusion intrinsic susceptibility-weighted (SWI) MRI and dynamic contrast-enhanced (DCE) MRI. Blood samples were obtained at the time of MRI scanning and two further time points for measuring Hb and a panel of serum cytokine markers of tumour hypoxia. 3D T2* and Ktrans maps were calculated from the MRI data for primary tumours and cervical lymph node metastases.Results: PRCT produced no change (11 patients) or reduced (1 patient) T2* (tumour oxygenation) in 12 of the 16 (75%) evaluable primary tumours. Three of the four patients with improved tumour oxygenation progressed or had partial response following treatment completion. There were variable changes in Ktrans (tumour perfusion or vessel permeability) following PRCT that were of small magnitude for most tumours. Pre- and Post-PRCT levels of measured cytokines were not significantly different.Conclusions: This study suggests that PRCT during radical CRT for HNSCC does not improve tumour oxygenation. Therefore, oncologists should consider changing practice according to NICE and American Association of Blood Banks guidelines on PRCT for anaemia. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

148. DARS: a phase III randomised multicentre study of dysphagia- optimised intensitymodulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Author

Petkar, Imran, Rooney, Keith, Roe, Justin W. G., Patterson, Joanne M., Bernstein, David, Tyler, Justine M., Emson, Marie A., Morden, James P., Mertens, Kathrin, Miles, Elizabeth, Beasley, Matthew, Roques, Tom, Bhide, Shreerang A., Newbold, Kate L., Harrington, Kevin J., Hall, Emma, and Nutting, Christopher M.

Subjects
HEAD & neck cancer treatment, DEGLUTITION disorders, CHEMORADIOTHERAPY, QUALITY of life, PHARYNGEAL cancer, CANCER treatment
Abstract

Background: Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients' quality of life. Single arm studies have shown that the dosimetric sparing of critical swallowing structures such as the pharyngeal constrictor muscle and supraglottic larynx can translate to better functional outcomes. However, there are no current randomised studies to confirm the benefits of such swallow sparing strategies. The aim of Dysphagia/Aspiration at risk structures (DARS) trial is to determine whether reducing the dose to the pharyngeal constrictors with dysphagia-optimised intensity- modulated radiotherapy (Do-IMRT) will lead to an improvement in long- term swallowing function without having any detrimental impact on diseasespecific survival outcomes. Methods/design: The DARS trial (CRUK/14/014) is a phase III multicentre randomised controlled trial (RCT) for patients undergoing primary (chemo) radiotherapy for T1-4, N0-3, M0 pharyngeal cancers. Patients will be randomised (1:1 ratio) to either standard IMRT (S-IMRT) or Do-IMRT. Radiotherapy doses will be the same in both groups; however in patients allocated to Do-IMRT, irradiation of the pharyngeal musculature will be reduced by delivering IMRT identifying the pharyngeal muscles as organs at risk. The primary endpoint of the trial is the difference in the mean MD Anderson Dysphagia Inventory (MDADI) composite score, a patient-reported outcome, measured at 12 months post radiotherapy. Secondary endpoints include prospective and longitudinal evaluation of swallow outcomes incorporating a range of subjective and objective assessments, quality of life measures, locoregional control and overall survival. Patients and speech and language therapists (SLTs) will both be blinded to treatment allocation arm to minimise outcome-reporting bias. Discussion: DARS is the first RCT investigating the effect of swallow sparing strategies on improving long-term swallowing outcomes in pharyngeal cancers. An integral part of the study is the multidimensional approach to swallowing assessment, providing robust data for the standardisation of future swallow outcome measures. A translational sub- study, which may lead to the development of future predictive and prognostic biomarkers, is also planned. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

149. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response.

Author

Ball, Douglas Wilmot, primary, Sherman, Steven I., additional, Jarzab, Barbara, additional, Cabanillas, Maria E., additional, Martins, Renato, additional, Shah, Manisha H., additional, Bodenner, Donald, additional, Newbold, Kate, additional, Licitra, Lisa F., additional, Topliss, Duncan, additional, Allison, Roger, additional, Kadowaki, Tadashi, additional, Funahashi, Yasuhiro, additional, Matijevic, Mark, additional, Sachdev, Pallavi, additional, O'Brien, James P., additional, and Schlumberger, Martin, additional

Published
2012
Full Text
View/download PDF

150. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).

Author

Schlumberger, Martin, primary, Jarzab, Barbara, additional, Cabanillas, Maria E., additional, Robinson, Bruce, additional, Pacini, Furio, additional, Ball, Douglas Wilmot, additional, McCaffrey, Judith C, additional, Newbold, Kate, additional, Allison, Roger, additional, Martins, Renato, additional, Licitra, Lisa F., additional, Shah, Manisha H., additional, Bodenner, Donald, additional, Elisei, Rossella, additional, Burmeister, Lynn A., additional, Funahashi, Yasuhiro, additional, Sellecchia, Rita, additional, Andresen, Corina, additional, O'Brien, James P., additional, and Sherman, Steven I., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results